51 results about "Cutaneous condition" patented technology

The invention provides a skin disease auxiliary evaluation system and device, a storage medium and a program product, and relates to the technical field of edge computation.The skin disease auxiliary evaluation system is deployed on a terminal device and comprises a feature extraction module, a feature extraction module and an evaluation module, obtaining semantic feature information corresponding to a disease description text in the skin disease information and image feature information corresponding to an affected part image in the skin disease information; the feature fusion module is used for associating the semantic feature information with the image feature information based on a cross attention mechanism to generate first multi-mode fusion feature information of the skin disease to be evaluated; and the large language model evaluation module is used for generating an evaluation result corresponding to the to-be-evaluated skin disease through a first large language model based on the first multi-mode fusion feature information.

Provided herein are systems and methods for identifying a disease or disorder of a patient, identifying if a patient is likely to respond to a treatment for the disease or disorder, and / or predicting the clinical outcome of the disease or disorder of a patient. Systems and methods described herein may be directed to patients with different chronic conditions, inflammatory conditions, and / or autoimmune conditions. Systems and methods described herein may be directed to patients with a dermatological condition.

Disclosed are effective, non-irritating, skincare formulations containing an alpha hydroxy acid and urea or a urea derivative for topical application to the skin. The disclosed topical formulations provide enhanced penetration of the active ingredients to the skin for the treatment of amenable skin conditions, such as very dry skin and keratosis pilaris, as well as for improvement of aesthetic skin properties. Also provided are methods for therapeutic treatment of dermatological conditions by topically applying a formulation comprising (% w / w) at least 10% alpha hydroxy acid and at least 10% urea. The formulations may be cream emulsions, spray-ons, among other delivery systems.

The present invention relates to an antimicrobial and healing formulation for skin, designed to effectively target and treat skin conditions such as acne caused by Cutibacterium acnes, cold sore lesions due to the herpes simplex virus, and superficial wounds. This unique formulation combines antimicrobial agents, plant extracts and essential oils in specific proportions in order to exert a synergistic action, enhancing their individual efficacy in the treatment of skin conditions and promoting skin healing. The innovative formulation composed of niaouli (Melaleuca viridiflora) essential oil and tea tree (Melaleuca alternifolia) essential oil, chlorhexidine digluconate, Hamamelis virginiana extract, panthenol, glycerol, and propylene glycol. Each ingredient has been selected for its proven pharmacological properties and its synergistic potential. The formulation works in concert to reduce microbial load, alleviate inflammation, and accelerate skin healing, while providing a gentle and effective application.

A topical application of nitric oxide may be provided by two separate containers, each containing an active component media to produce nitric oxide when combined. For example, a nitrite component media may be contained in one dispenser and an acidified component media may be contained in another dispenser. Each dispenser may dispense the respective component media as a foam or a solution. They can be combined to initiate the production of nitric oxide and the mixture of resultant foam is applied topically to treat various skin disorders or wounds.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

A method for mapping one or more cutaneous conditions of a cutaneous surface may include: identifying a body map; identifying one or more body regions corresponding to the body map; identifying at least one representation corresponding to the one or more body regions; identifying one or more icons corresponding to the at least one representation; and defining the one or more icons on the at least one representation.

Provided herein are compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or dermatologic skin conditions. The compositions include black willow bark extract, cat's claw extract, and dragon's blood extract. The compositions ameliorate skin conditions including acne, rosacea, blemish, dermatitis, eczema, or the like.

The present invention relates to a patch containing an improved release liner for the treatment of various skin conditions.

The present invention provides a formulation for application to the skin and pharmaceutical uses of the formulations of the invention. The present invention also provides methods of delivering a medicament to a subject and kits for treating a subject having a skin condition.

The present invention relates to a composition, in particular a cosmetic composition, comprising, in a physiologically acceptable medium, at least one endolysin derived from Staphylococcus aureus bacteriophage and at least one oil other than liquid paraffin. The invention also relates to the use of such a composition for the prevention and / or treatment of skin conditions associated with colonization of Staphylococcus aureus in a subject in need thereof, and in particular for the prevention and / or treatment of acne and / or eczema in a subject, and to a non-therapeutic cosmetic method for caring for keratin materials, in particular skin, it comprises at least one step of topically applying such a composition to the keratin material.

The present invention provides a medical implant, comprising (a) a matrix layer comprising chitosan; and (b) a reinforcement structure comprising polymer filaments or polymer fibers, whereby the reinforcement structure is incorporated into the matrix layer. The invention further relates to the medical implant for use in the treatment of ophthalmological diseases or skin disorders. The invention finally relates to a method for producing the medical implant of the invention.

The present disclosure describes methods of treating a skin disorder in a subject in need thereof and methods of locally suppressing an immune response in a tissue of a subject in need thereof. The methods can include contacting a microneedle array comprising a plurality of microneedles with a skin surface of the subject, wherein the plurality of microneedles comprises: i) a degradable hyaluronic acid polymer comprising a disulfide bond, and ii) a therapeutic agent; and applying pressure on the microneedle array such that the plurality of microneedles penetrates the skin surface, thereby releasing the therapeutic agent beneath the skin surface while simultaneously capturing ISF for successive analysis.

This method involves treating a patient's skin condition or disease by topically applying a pharmaceutical composition containing roflumilast. Treatment methods include once-daily application of the roflumilast composition for a period of time, followed by twice-weekly application of the roflumilast composition as a maintenance dosing regimen.

Modulated light therapy devices for treatment of dermatological disorders of the scalp are provided. An exemplary device includes a flexible printed circuit board (FPCB) supporting at least one light emitting device having an emitter height. The FPCB includes multiple interconnected panels and bending regions defined in and between at least some of the interconnected panels as to allow the FPCB to be configured in a concave shape to cover at least a portion of a cranial vertex of the patient. At least one light-transmissive layer proximate to the FPCB is configured to transmit (e.g., incoherent) light emissions generated by at least one light emitting device. At least one standoff is configured to be arranged between the FPCB and the scalp of the patient, wherein the at least one standoff includes a standoff height that exceeds the emitter height.

Provided herein are polyphenol-enriched lettuce powders comprising particles of a polyphenol-enriched lettuce or extract, wherein the polyphenol-enriched lettuce comprises from 40-280 mg / g of polyphenols. The polyphenols include any combination of a chlorogenic acid, a neochlorogenic acid, a chicoric acid, a quercetin, a quercetin derivative, and an anthocyanin. The disclosure also provides compositions and methods of using the polyphenol-enriched lettuce powders to promote wound healing and treat inflammation and skin disorders.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

A method for mapping one or more cutaneous conditions of a cutaneous surface may include: identifying a body map; identifying one or more body regions corresponding to the body map; identifying at least one representation corresponding to the one or more body regions; identifying one or more icons corresponding to the at least one representation;and defining the one or more icons on the at least one representation.

The present disclosure relates to a method of treating a neutrophilic skin condition in a subject. The methods comprise subcutaneous administration of a fixed dose of an antibody that inhibits granulocyte colony stimulating factor (G-CSF) signaling to the subject.

Compounds and methods related to the prevention and treatment of diseases and conditions, some of which are facilitated by melanogenesis are disclosed. Specifically, the present subject matter includes a series of compounds and compositions and their use for anti-melanogenic and antioxidant activity. This subject matter also includes the treatment of skin disorder due to acne vulgaris and related inflammatory and post inflammatory hyperpigmentation. Methods for synthesizing contemplated compounds are also disclosed.

Provided herein are pharmaceutical compositions of a magnesium salt and alpha lipoic acid and / or methanesulfonylmethane (MSM) useful for treating, preventing, or reducing the severity of viral infections and / or skin conditions. Also provided are methods for preparing the pharmaceutical compositions, and methods of using the pharmaceutical compositions in therapy.

The present disclosure provides compounds and pharmaceutically acceptable salts thereof for the inhibition of CYP26B1. Aspects of the present disclosure also include methods of using the compounds in the treatment of diseases or conditions including, but not limited to, skin conditions, cancer, neurological conditions, heterotopic ossification (HO), progressive ossified fibrodysplasia (FOP), multiple osteochondroma, and ocular diseases or conditions, including meibomian gland dysfunction and dry eye disease.

Embodiments of the present disclosure generally relate to a new class of daptide antibiotics and compositions that include the daptide antibiotics. Embodiments described herein also generally relate to methods of treating various diseases or medical conditions in a patient utilizing the new class of daptide antibiotics and compositions thereof. In an embodiment, a composition for treating a skin condition in a patient is provided. The composition includes a daptide comprising: a dimethylated 7V-terminus; a Dmp-modified C- terminus; a dehydrobutyrine residue positioned between the dimethylated 7V-terminus and the Dmp-modified C-terminus; at least one alanine (A) residue or at least one dehydroalanine (Dha) residue positioned between the dimethylated 7V-terminus and the Dmp-modified C- terminus; and at least one amino acid residue positioned between the dimethylated 7V-terminus and the Dmp-modified C-terminus. In another embodiment is provided a daptide bacteriocin composition that is antimicrobial against a staphylococcal skin bacteria in a patient.

A pharmacological agent and method for treatment of cancer and vascular-related disorders of skin and colon are described. The pharmacological agent, which is a small molecule that targets and inhibits both RhoJ and CDC42 signaling, demonstrates potent anti-vascular effects in normal skin, colon, and tumors, combined with low toxicity, especially as compared to BRAF inhibitors (such as, vemurafenib used in melanoma treatments), selective CDC42 inhibitors (such as CASIN), and VEGF inhibitors (known as anti-vascular agents, such as, for example, linifanib). As such, the pharmacological agent is particularly suited for applications related to treating cancer, as well as disorders of the skin and colon that exhibit increased vasculature.

Disclosed is a multiphasic mixture that generates nitric acid in situ for the treatment of topical dermatological conditions.

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

Suggested is a non-therapeutic method for preventing, mitigating or treating PTGS2-induced disorders of human skin and related dysfunctions, comprising or consisting of the following step: —applying a working amount of a carnosine compound according to formula (I) in which R1 stands for H or CH3 and R2 for H or COOH, to human skin

There is a topical skin care composition composed of a blend of hydroxytyrosol, green coffee extract and green tea leaf extract for use in the modulation of epidermal cellular gene expression profiles to alleviate various skin disorders and significantly reduce the resultant disease symptoms and reduce the rate at which the skin ages. More specifically, the topical skin care composition has hydroxytyrosol at a concentration range of 0.1% w / w to 0.75% w / w, green tea extract at a concentration range of 0.025% w / w to 0.1% w / w; and green coffee bean extract at a concentration range of 0.025% w / w to less than 0.2% w / w. A method of treating one or more of the hallmarks of ageing and skin degradation and collagen and elasticity as a single dosage from a pharmaceutical composition is described, as well as a method of activating skin cells having the step of applying the topical skin composition.